DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative...

Full description

Saved in:
Bibliographic Details
Main Authors YIN, Shen, HRISTOPOULOS, Maria, WEI, Michael, SIMKO, Stephen, CHU, Yu-Waye, TO, Iris, TOTPAL, Klara, LI, Chi-Chung, WANG, Hong, BENDER, Brendan, CHEN, Xi, O'HEAR, Carol
Format Patent
LanguageEnglish
French
Published 12.05.2022
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate. La présente invention concerne le traitement de sujets ayant des troubles prolifératifs cellulaires CD20-positifs (par ex., des troubles prolifératifs des lymphocytes B, tels que les lymphomes non hodgkiniens). Plus spécifiquement, l'invention concerne le traitement de sujets ayant un trouble prolifératif cellulaire CD20-positifs (par ex., un trouble prolifératif des lymphocytes B) par administration d'une combinaison d'un anticorps bispécifique anti-CD20/anti-CD3 et d'un conjugué anticorps anti-CD79b-médicament.
Bibliography:Application Number: WO2021US57714